Eli Lilly had a blockbuster drug for sepsis that would save millions of lives. 10 years later, the FDA recommended that Xigris be withdrawn from the market. Remarkably,  Eli Lilly profited from this ineffective drug most of the time it was under patent. What lesson from Xigris’s failure can we learn about the immune system, about sepsis, and evolution?

Eli Lilly had a blockbuster drug for sepsis that would save millions of lives. 10 years later, the FDA recommended that Xigris be withdrawn from the market. Remarkably, Eli Lilly profited from this ineffective drug most of the time it was under patent. What lesson from Xigris’s failure can we learn about the immune system, about sepsis, and evolution?

#2 The Evolutionary Lesson of Xigris

Joe Alcock and guests talk about evolution, adaptation, medical care, epidemics, emerging diseases, and the microbiome.

Share #2 The Evolutionary Lesson of Xigris

Sign up to save your podcasts

#2 The Evolutionary Lesson of Xigris

#2 The Evolutionary Lesson of Xigris